A5094051319- Prostate Cancer Treatment and Research
- Medical Imaging Techniques and Applications
- Prostate Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
P.A. Hertzen Moscow Oncology Research Institute
2024
Ministry of Health of the Russian Federation
2024
It is established that prostate-specific membrane antigen (PSMA), despite its name, expressed in many tissues other than the prostate gland, both within physiological conditions and various pathological processes. Additionally, apart from cancer, malignant tumors are characterized by increased PSMA expression which, according to authors, associated with neoangiogenesis. These factors reflected results of PSMA-radioligand imaging require comprehensive approach image interpretation including...
Оne of the most commonly used fluorine‑18 labeled prostate-specific membrane antigen (PSMA) ligands in positron emission tomography combined with computed (PET/CT) is [ 18 F]PSMA‑1007. In comparison to other clinically available PSMA radioligands characterized by renal clearance, F]PSMA‑1007 exhibits predominantly hepatobiliary excretion. It allows a better assessment pelvic area patients prostate cancer (PCa). Nevertheless, our clinical practice, we routinely observed notably high uptake...